# Catalent (Novo Holdings)

Source: https://onco.cc/companies/catalent/  
OnCo record `catalent` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Catalent, of Somerset, New Jersey, is a contract manufacturer that fills and finishes sterile injectables and makes biologics and cell and gene therapies; Novo Holdings bought it in 2024 and moved three sites to Novo Nordisk. The diversion of fill-finish capacity to obesity drugs may squeeze oncology products.

## Summary

Catalent, based in Somerset, New Jersey, is a fill-finish and gene therapy CDMO acquired by Novo Holdings in 2024, with three sites transferred to Novo Nordisk. It manufactures sterile injectables, biologics and cell and gene therapies, and the capacity shifts that followed the Novo deal affected some oncology sponsors. OnCo links it to sterile fill-finish and lyophilisation and to viral vector manufacturing. Whether the diversion of fill-finish capacity to obesity drugs squeezes oncology products is the open question the acquisition raised. The fill-finish technology page carries the wider picture.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: supporting
- HQ: Somerset, NJ
- Type: cro-services
- Website: https://www.catalent.com

## Sources

- Official website: https://www.catalent.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [GMP, inspections, Form 483s and warning letters](https://onco.cc/technologies/pharmaceutical-gmp-inspections/), [Sterile fill-finish and lyophilisation](https://onco.cc/technologies/sterile-fill-finish/), [Viral vector manufacturing (lentiviral, retroviral, AAV)](https://onco.cc/technologies/viral-vector-manufacturing/)

---
JSON: https://onco.cc/api/v1/entities/catalent.json